Reata RGLS8429 ADPKD Clinical Development 2024

Presentation on RGLS8429, a clinical-stage therapeutic targeting autosomal dominant polycystic kidney disease (ADPKD), an orphan indication with high unmet medical need. The document outlines disease pathology, patient population of ~160K diagnosed individuals in the U.S., and the significant disease burden with 50% of patients progressing to end-stage renal disease by age 60.